Ongoing trials

Clinical Study Principal Investigator
Protocol No: CBTL719CIN01
ALPelisib INdia Safety STudy (ALPINIST) : A Phase IV, prospective, multicenter, open-label, non-comparative, interventional study to assess the safety of alpelisib plus fulvestrant, in men and post-menopausal women with HR- positive, HER2-negative, advanced or metastatic Breast Cancer (ABC or MBC) with a PIK3CA mutation, whose disease has progressed on or after endocrine based treatment.
Dr. Praveena Voonna
Protocol No: BIO-PERTUZ-301_HAB98922
A Multicenter, Double-Blind, Randomized, Parallel-group, Phase 3 Study to Compare the Efficacy and Safety of the Proposed Biosimilar PERT-IJS and EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Patients with Hormone Receptor Negative (HR-ve) Human Epidermal Growth Factor Receptor 2(HER2)‑positive Early Stage or Locally Advanced Breast Cancer.
Dr. Praveena Voonna
Protocol No: CJDQ443B12301
KontRASt-02: A randomized, controlled, open label, phase III study evaluating the efficacy and safety of JDQ443 versus docetaxel in previously treated subjects with locally advanced or metastatic KRAS G12C mutant non-small cell lung cancer.
Dr. Kishore Kumar Kota
Protocol No: NAT2694P2
A Phase II Clinical Study to evaluate the efficacy and safety of NRC-2694-A in patients with recurrent Head and Neck Squamous Cell Carcinoma.
Dr. Rajani Priya Yedla
Protocol No. 0063-17
Study Title: A global, multicenter, three arms, open-label randomized study to evaluate the efficacy and safety of Nanosomal Docetaxel Lipid Suspension compared to Taxotere® (Docetaxel Injection Concentrate) in triple-negative breast cancer patients with locally advanced or metastatic breast cancer after failure to prior chemotherapy.
Dr. Praveena Voonna
Protocol No. 1045-18
Study Title: A phase III, two arm, multi centric, randomized, open label, parallel study to compare pharmacodynamics of Goserelin 10.8 mg Injection (Eurofarma Laboratórios S.A) administered subcutaneously with the reference drug ZOLADEX® 10.8 mg Injection (AstraZeneca) in patients with advanced prostate cancer.
Dr. Kota Kishore Kumar
Protocol No. MW230015
Study Title: An open label, multi-center, randomized, two- treatment, two-period, two-sequence, two-way cross-over, single dose, Bioequivalence (BE) study with pharmacokinetic (PK) endpoints of Paclitaxel 100mg/vial injectable suspension at a dose of 260 mg/m2 of Anbison Lab, China with ABRAXANE® 100mg/vial for Injectable suspension at a dose of 260 mg/m2 of Celgene Corporation Summit, NJ 07901 in subject with metastatic Breast cancer after failure of combination chemotherapy or relapse within 6 months of adjuvant chemotherapy.
Dr. Kota Kishore Kumar
Protocol No. NU-01-001
Study Title: A phase I/III, randomised, double blind, multicentre, parallel arm, clinical study comparing the efficacy, safety, immunogenicity and pharmacokinetics of proposed biosimilar nivolumab (DRL_NU) with nivolumab reference medicinal product (OPDIVO®) administered by the intravenous route in patients previously treated for locally advanced or metastatic squamous cell non-small cell lung cancer (NSCLC).
Dr. Murali Krishna Voonna